Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 Apr;65(4).
doi: 10.1002/pbc.26909. Epub 2017 Dec 12.

Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia

Trausti Oskarsson  1   2 , Stefan Söderhäll  1   2 , Johan Arvidson  3 , Erik Forestier  4 , Thomas Leth Frandsen  5 , Marit Hellebostad  6 , Päivi Lähteenmäki  7 , Ólafur G Jónsson  8 , Ida Hed Myrberg  2 , Mats Heyman  1   2 ; Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL Relapse Working Group
Affiliations
Clinical Trial

Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia

Trausti Oskarsson et al. Pediatr Blood Cancer. 2018 Apr.

Abstract

Background: Treatment of relapsed childhood acute lymphoblastic leukemia (ALL) is particularly challenging due to the high treatment intensity needed to induce and sustain a second remission. To improve results, it is important to understand how treatment-related toxicity impacts survival.

Procedure: In this retrospective population-based study, we described the causes of death and estimated the risk for treatment-related mortality in patients with first relapse of childhood ALL in the Nordic Society of Paediatric Haematology and Oncology ALL-92 and ALL-2000 trials.

Results: Among the 483 patients who received relapse treatment with curative intent, we identified 52 patients (10.8%) who died of treatment-related causes. Twelve of these died before achieving second remission and 40 died in second remission. Infections were the cause of death in 38 patients (73.1%), predominantly bacterial infections during the chemotherapy phases of the relapse treatment. Viral infections were more common following hematopoietic stem cell transplantation (HSCT) in second remission. Independent risk factors for treatment-related mortality were as follows: high-risk stratification at relapse (hazard ratio [HR] 2.2; 95% confidence interval [CI] 1.3-3.9; P < 0.01), unfavorable cytogenetic aberrations (HR 3.4; 95% CI 1.3-9.2; P = 0.01), and HSCT (HR 4.64; 95% CI 2.17-9.92; P < 0.001). In contrast to previous findings, we did not observe any statistically significant sex or age differences. Interestingly, none of the 17 patients with Down syndrome died of treatment-related causes.

Conclusions: Fatal treatment complications contribute significantly to the poor overall survival after relapse. Implementation of novel therapies with reduced toxicity and aggressive supportive care management are important to improve survival in relapsed childhood ALL.

Keywords: acute lymphoblastic leukemia; hematopoietic stem cell transplantation; infection; pediatric; relapse; treatment-related mortality.

PubMed Disclaimer

LinkOut - more resources